TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06917079: BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 665 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06917079 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06917079 Rescue Dossier →